Clinical Trial Update: Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ferric carboxymaltose (FCM) versus standard of care for iron deficiency anemia in chronic kidney disease; results completed with posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: American Regent, Inc. | Conditions: Anemia | Phase 3 | Status: COMPLETED | Results posted: 2015-05-13